Sign in
ARGX Stock Price, Chart, Stats & News
argenx SE
Save
argenx SE (ARGX) does not currently pay a dividend.
57.16B
Market cap
33.14x
Current P/E
25.91x
Forward P/E
ARGX chart
Fundamentals
Gross margin | 79.70% |
Operating margin | 20.32% |
Pretax margin | 26.43% |
Net margin | 39.25% |
Effective tax rate | -48.30% |
ROA | 24.82% |
ROE | 34.18% |
D/E | 0.01x |
Interest coverage ratio | 233.37x |
ARGX valuation
P/E | 33.14x |
P/S | 7.79x |
P/B | 5.80x |
P/CF | 47.84x |
P/FCF | 48.60x |
P/OCF | 47.84x |
PEG | 0.20x |
EV multiple | 28.28x |
About
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions.
Similar securities
Based on sector and market capitalization
Report issue